Aktie A3D10N 3D MEDICINES INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen 3D Medicines Inc.

Aktien

A3D10N

KYG8872R1011

1244

Markt geschlossen - Hong Kong S.E.
Andere Börsenplätze
 10:08:32 29.05.2024 		% 5 Tage % 1. Jan.
6,7 HKD -5,37 % Intraday Chart für 3D Medicines Inc. -6,69 % -12,30 %
29.03. 3D Medicines' Verlust 2023 halbiert sich fast, während der Umsatz um 12% steigt MT
28.03. 3D Medicines Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12%
3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Simcere Pharmaceutical’s Profit to Fall Up to 27% in 2023
Simcere Pharmaceutical Expects Up to 26% Fall in 2023 Profit; Shares Slide 3%
3D Medicines Inc. commences an Equity Buyback Plan for 25,605,700 shares, representing 10% of its issued share capital, under the authorization approved on June 26, 2023.
Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 for Multiple Geographies around the World
Alphamab Oncology and 3Dmedicines Enters into A Licensing Agreement with Glenmark for KN035
Alphamab Oncology Unit, 3D Medicines Grants Glenmark Unit License to Commercialize Sarcoma Injectable
3D Medicines Unit Receives Repayment for 60 Million Yuan Loan
3D Medicines Subsidiary Extends 60 Million Yuan Loan; Shares Fall 3%
SELLAS Life Sciences Seeks Arbitration in Dispute with 3D Medicines
3D Medicines Inc. Announces Change of Principal Place of Business in Hong Kong
35,992,364 Ordinary Shares of 3D Medicines Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2023.
3D Medicines Gets US FDA's Nod to Trial Envafolimab; Shares Soar 24%
3D Medicines Inc. Receives Approval from Fda to Proceed with Aglobal Phase Iii Trial for Treatment of the First Line Mismatch Repair ProficientAdvanced or Recurrent Endometrial Cancer
Sellas Life Sciences Expects to Complete Patient Enrollment for Phase 3 REGAL Trial in November
128,967,484 Ordinary Shares of 3D Medicines Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2023.
3D Medicines Invests Over $21 Million of Surplus Cash
3D Medicines Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
3D Medicines Raises HK$226.8 Million from Share Placement
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3D10N Aktie
  4. Nachrichten 3D Medicines Inc.
  5. Andere Sprachen